1. Home
  2. SUPN vs KYMR Comparison

SUPN vs KYMR Comparison

Compare SUPN & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • KYMR
  • Stock Information
  • Founded
  • SUPN 2005
  • KYMR 2015
  • Country
  • SUPN United States
  • KYMR United States
  • Employees
  • SUPN N/A
  • KYMR N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • KYMR Medicinal Chemicals and Botanical Products
  • Sector
  • SUPN Health Care
  • KYMR Health Care
  • Exchange
  • SUPN Nasdaq
  • KYMR Nasdaq
  • Market Cap
  • SUPN 1.9B
  • KYMR 1.8B
  • IPO Year
  • SUPN 2012
  • KYMR 2020
  • Fundamental
  • Price
  • SUPN $32.28
  • KYMR $45.87
  • Analyst Decision
  • SUPN Hold
  • KYMR Strong Buy
  • Analyst Count
  • SUPN 2
  • KYMR 16
  • Target Price
  • SUPN $36.00
  • KYMR $59.38
  • AVG Volume (30 Days)
  • SUPN 529.3K
  • KYMR 1.1M
  • Earning Date
  • SUPN 08-05-2025
  • KYMR 08-06-2025
  • Dividend Yield
  • SUPN N/A
  • KYMR N/A
  • EPS Growth
  • SUPN N/A
  • KYMR N/A
  • EPS
  • SUPN 1.11
  • KYMR N/A
  • Revenue
  • SUPN $667,997,000.00
  • KYMR $58,885,000.00
  • Revenue This Year
  • SUPN N/A
  • KYMR $43.38
  • Revenue Next Year
  • SUPN $12.02
  • KYMR $10.97
  • P/E Ratio
  • SUPN $29.32
  • KYMR N/A
  • Revenue Growth
  • SUPN 11.82
  • KYMR N/A
  • 52 Week Low
  • SUPN $25.55
  • KYMR $19.45
  • 52 Week High
  • SUPN $40.28
  • KYMR $53.27
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 48.28
  • KYMR 67.58
  • Support Level
  • SUPN $31.56
  • KYMR $45.80
  • Resistance Level
  • SUPN $33.15
  • KYMR $47.51
  • Average True Range (ATR)
  • SUPN 0.92
  • KYMR 2.86
  • MACD
  • SUPN -0.03
  • KYMR -0.03
  • Stochastic Oscillator
  • SUPN 40.34
  • KYMR 67.19

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Share on Social Networks: